Navigation Links
DiagnoCure announces fourth quarter 2008 and year-end results
Date:12/17/2008

ss per share (0.09) (0.09) (0.33) (0.24) ------------------------------------------------------------------------- Weighted average number of common shares outstanding 42,794,475 41,718,463 42,272,320 38,422,096 ------------------------------------------------------------------------- Balance sheets As of October 31 ------------------------------------------------------------------------- 2008 2007 ------------------------------------------------------------------------- Cash, cash equivalents, temporary and long-term investments 20,130,705 32,867,526 ------------------------------------------------------------------------- Total assets 33,146,066 43,585,440 ------------------------------------------------------------------------- Shareholders' equity 29,639,848 40,191,471 ------------------------------------------------------------------------- Number of common shares outstanding 42,794,475 41,718,463 -------------------------------------------------------------------------

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. In August 2008, DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the d
'/>"/>

SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. DiagnoCure to host Q2 2008 earnings conference call and webcast
3. DiagnoCure announces second quarter 2008 results
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
6. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
7. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
8. DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... is to soon go on Phase I trial. It maybe ... Biocon, Ms.Kiran Mazumdar Shaw. ,Ms.Shaw was speaking ... Foundation(MDRF) on awards for innovation and R&D.// There are close ... to diabetes should always bear this in mind and develop ...
... underwent a successful life-changing operation in India and returned home ... being// overweight. ,David Rogers, 62, from Abbeydale, Worcestershire, ... for the double hip and knee replacements that he desperately ... was about 37 kg too heavy for the surgery. ...
... two new genes found with breast tumors can predict the ... In the report appearing in he April 1 issue of ... identify women at risk for an early relapse of breast ... previously discovered as a potential marker of relapse in hormone-receptor ...
... the peels of fruits and vegetables, which are thrown away ... better to have a second thought next time, when you ... and keeps you young. ,As reported in foodconsumer.org ... the United States to $2.7 billion in 2003. Top of ...
... have bettered among the teenagers and young adults (TYAs) in ... than in those where people have to pay for their ... system of health insurance for all, regardless of age, meant ... than they were in the USA. ,Prof ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 3
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today reported financial ... 2014.  Global revenue for the Company,s Urgent ... a new quarterly revenue record, as compared to $3.9 ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... third-generation immunoassay system combines continuous ... processing with a broad testing ... higher volume clinical laboratories to ... tests simultaneously, as well as ...
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
...
Medicine Products: